Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06513026 · ClinicalTrials.gov registry record · NA

Milk for Diabetes Prevention

A NA study, sponsored by Albert Einstein College of Medicine.

Recruiting
Registry status
NA
Development phase
40
Enrollment target

NCT06513026 is a NA study that is actively recruiting participants, run by Albert Einstein College of Medicine. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06513026, a NA study, is actively recruiting participants, sponsored by Albert Einstein College of Medicine.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

Individuals with lactase non-persistence (LNP; determined by a functional variant in the LCT gene \[rs4988235, GG genotype\]) are susceptible to lactose intolerance in adulthood due to deficiency of lactase, the enzyme which digests milk lactose sugars. However, many LNP individuals still drink ≥1 cup of milk daily. Recent analysis in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) found that consumption of 1 serving (cup) of milk/day was associated with \~30% lower risk of type 2 diabetes among LNP individuals, but not among individuals with lactase persistence (LP). This beneficial effect might be partially explained by favorable alterations in gut microbiota and related metabolites associated with higher milk consumption among LNP individuals. Based on these observational study findings, the investigator team proposes to conduct a randomized, controlled trial of lactose-containing vs. lactose-free milk in LNP individuals with pre-diabetes, to comprehensively investigate the effects of milk intake on the gut microbiome and glycemic outcomes.

Interventions

  • DIETARY_SUPPLEMENT Lactose-Containing Milk
  • DIETARY_SUPPLEMENT Lactose-Free Milk

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-05-15
Est. Completion 2028-04
Phase NA

Sponsor

Albert Einstein College of Medicine

175 total trials

What the Registry Record Tells You About NCT06513026

The ClinicalTrials.gov registry entry for NCT06513026 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Lactose-Containing Milk is the first listed.

NCT06513026 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06513026 about?

NCT06513026 is a clinical study titled "Milk for Diabetes Prevention". Individuals with lactase non-persistence (LNP; determined by a functional variant in the LCT gene \[rs4988235, GG genotype\]) are susceptible to lactose intolerance in adulthood due to deficiency of lactase, the enzyme which digests milk lactose sugars. However, many LNP individuals still drink ≥1 c...

What is the current status of trial NCT06513026?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-05-15. Estimated completion is 2028-04.

What interventions are being tested in trial NCT06513026?

The interventions under investigation include: Lactose-Containing Milk (DIETARY_SUPPLEMENT), Lactose-Free Milk (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06513026?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.